Tricking the balance: NK cells in anti-cancer immunity.
Natural Killer (NK) cells are classically considered innate immune effector cells involved in the first line of defense against infected and malignant cells. More recently, NK cells have emerged to acquire properties of adaptive immunity in response to certain viral infections such as expansion of specific NK cell subsets and long-lasting virus-specific responses to secondary challenges. NK cells distinguish healthy cells from abnormal cells by measuring the net input of activating and inhibitory signals perceived from target cells through NK cell surface receptors. Acquisition of activating ligands in combination with reduced expression of MHC class I molecules on virus-infected and cancer cells activates NK cell cytotoxicity and release of immunostimulatory cytokines like IFN-γ. In the cancer microenvironment however, NK cells become functionally impaired by inhibitory factors produced by immunosuppressive immune cells and cancer cells. Here we review recent progress on the role of NK cells in cancer immunity. We describe regulatory factors of the tumor microenvironment on NK cell function which determine cancer cell destruction or escape from immune recognition. Finally, recent strategies that focus on exploiting NK cell anti-cancer responses for immunotherapeutic approaches are outlined.
Innate Immunity Group, D080, German Cancer Research Center, DKFZ Im Neuenheimer Feld 280, 69221 Heidelberg, Germany. Electronic address: j.pahl@dkfz.de.
Jens
J
Pahl
Innate Immunity Group, D080, German Cancer Research Center, DKFZ Im Neuenheimer Feld 280, 69221 Heidelberg, Germany. Electronic address: a.cerwenka@dkfz.de.
Adelheid
A
Cerwenka
D056704:Adaptive Immunity; D000818:Animals; D016207:Cytokines / Q000378:metabolism; D003602:Cytotoxicity, Immunologic; D015395:Histocompatibility Antigens Class I / Q000235:genetics / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate; D007157:Immunologic Surveillance; D056747:Immunomodulation; D007167:Immunotherapy / Q000379:methods; D007694:Killer Cells, Natural / Q000276:immunology* / Q000378:metabolism*; D009369:Neoplasms / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D059016:Tumor Microenvironment / Q000276:immunology
D016207:Cytokines; D015395:Histocompatibility Antigens Class I
Cancer; Immunotherapy; Innate immunity; NK cell